Jared Holz, Mizuho Securities healthcare sector specialist, joins ‘Fast Money’ to talk controversy brewing at Biogen, Alzheimer’s drug approval roadblocks in Europe, and more.
Mizuho news from around the globe
Mizuho Global News
Jared Holz, Mizuho Securities healthcare sector specialist, joins ‘Fast Money’ to talk controversy brewing at Biogen, Alzheimer’s drug approval roadblocks in Europe, and more.